2025 MDA Clinical and Scientific Conference Del-zota (delpacibart zotadirsen) produced statistically significant increases in exon skipping and dystrophin levels in EXPLORE44®, a Phase 1/2 study in individuals with DMD44 Phase 3, Randomized, Global Study Assessing Efficacy and Safety of Del-desiran™ for the Treatment of Myotonic Dystrophy Type 1: HARBOR™ Trial Design